The shadow of generic challenges has repeatedly loomed above copyright’s blockbuster drug, Viagra, triggering questions about the future of similar pharmaceutical ventures. While first times saw significant returns, the exclusivity lapse has opened the way for cheaper alternatives, likely diminishing revenue and posing a real risk for shareholder